PACB Stock Overview
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Pacific Biosciences of California, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.25 |
| 52 Week High | US$14.20 |
| 52 Week Low | US$3.85 |
| Beta | 1.66 |
| 1 Month Change | 18.92% |
| 3 Month Change | 12.28% |
| 1 Year Change | -4.58% |
| 3 Year Change | 164.71% |
| 5 Year Change | 355.47% |
| Change since IPO | -31.57% |
Recent News & Updates
Recent updates
Time To Worry? Analysts Just Downgraded Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Outlook
Aug 08
Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio
Jul 27Is Pacific Biosciences of California (NASDAQ:PACB) Using Debt Sensibly?
Jul 11Pacific Biosciences Hit By Sentiment, But The Future Of Long-Read Sequencing Is Strong
Apr 05Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?
Feb 24Is Pacific Biosciences of California (NASDAQ:PACB) Weighed On By Its Debt Load?
Nov 2610% Short Interest In Pacific Biosciences Makes Sense
Nov 20Pacific Biosciences: Boom In Genome Sequencing Technology With 35% Upside
Aug 04Is Pacific Biosciences of California (NASDAQ:PACB) Using Too Much Debt?
Jun 01The Pullback In Pacific Biosciences Makes For A Much More Interesting Opportunity
May 26Pacific Biosciences of California's (NASDAQ:PACB) Earnings Are Built On Soft Foundations
Mar 05Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Intrinsic Value Is Potentially 25% Below Its Share Price
Jan 28PacBio, Invitae team up to develop genome-based testing offerings
Jan 13Pacific Biosciences of California creates two new management roles
Jan 08What Kind Of Shareholders Hold The Majority In Pacific Biosciences of California, Inc.'s (NASDAQ:PACB) Shares?
Dec 21Don't Be Fooled By Pacific Biosciences' Accounting Of Merger Termination With Illumina
Dec 15Shareholder Returns
| PACB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -2.0% | 1.5% | 1.6% |
| 1Y | -4.6% | -12.5% | -10.8% |
Return vs Industry: PACB exceeded the US Life Sciences industry which returned -12.5% over the past year.
Return vs Market: PACB exceeded the US Market which returned -10.8% over the past year.
Price Volatility
| PACB volatility | |
|---|---|
| PACB Average Weekly Movement | 12.9% |
| Life Sciences Industry Average Movement | 11.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: PACB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: PACB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 728 | Christian O. Henry | https://www.pacb.com |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio’s Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides.
Pacific Biosciences of California, Inc. Fundamentals Summary
| PACB fundamental statistics | |
|---|---|
| Market Cap | US$2.94b |
| Earnings (TTM) | -US$299.19m |
| Revenue (TTM) | US$136.97m |
21.4x
P/S Ratio-9.8x
P/E RatioIs PACB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PACB income statement (TTM) | |
|---|---|
| Revenue | US$136.97m |
| Cost of Revenue | US$75.58m |
| Gross Profit | US$61.39m |
| Other Expenses | US$360.59m |
| Earnings | -US$299.19m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 16, 2023
| Earnings per share (EPS) | -1.15 |
| Gross Margin | 44.82% |
| Net Profit Margin | -218.44% |
| Debt/Equity Ratio | 143.1% |
How did PACB perform over the long term?
See historical performance and comparison